Bakirtas, M. Et Al. 2025. Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety. Indian Journal of Hematology and Blood Transfusion .

Bakirtas, M., Hindilerden, I. Y., Ulu, B. U., Ekinci, O., Dogu, M. H., Aydogdu, I., ... BERBER, İ.(2025). Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety. Indian Journal of Hematology and Blood Transfusion .

Bakirtas, Mehmet Et Al. "Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety," Indian Journal of Hematology and Blood Transfusion , 2025

Bakirtas, Mehmet Et Al. "Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety." Indian Journal of Hematology and Blood Transfusion , 2025

Bakirtas, M. Et Al. (2025) . "Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety." Indian Journal of Hematology and Blood Transfusion .

@article{article, author={Mehmet Bakirtas Et Al. }, title={Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety}, journal={Indian Journal of Hematology and Blood Transfusion}, year=2025}